arbutin has been researched along with Lentigo* in 2 studies
1 trial(s) available for arbutin and Lentigo
| Article | Year |
|---|---|
A double-blind, placebo-controlled randomized trial of Serratulae quinquefoliae folium, a new source of β-arbutin, in selected skin hyperpigmentations.
Arbutin is one of the most effective lightening substances. Serratula quinquefolia is a new source of its β-anomer. The HPLC method showed that the solid content of this compound in the dried plant raw material accounts for 6.86%. The leaves of Serratula quinquefolia do not contain hydroquinone.. To assess the efficacy of the aqueous extract from' leaf of five-leaf serratula as a skin-lightening agent.. We did a randomized, placebo-controlled, double-blind trial. The study involved 102 women aged 26-55, with two kinds of hyperpigmentary diseases: melasma and lentigo solaris. Patients were randomly assigned to one of the treatment groups: a study group (N = 54) or a control group (N = 48). The study group applied the cream with the aqueous extract from leaf of five-leaf serratula containing 2.51% of arbutin. The cream was applied twice a day on the discolored side for 8 weeks.. The experimental data showed that the cream with the extract causes decreased level of melanin in the skin pigmentation spot. Clinical effect in the form of lightening and evening skin tone on the discolored side was observed in 75.86% of the female patients with melasma and 56.00 % of the female patients with lentigo solaris.. The cream with the aqueous extract from leaf of five-leaf serratula proved to be an effective and safe preparation for lightening skin discolorations (66.67 % of the female patients in the study group). Topics: Adult; Arbutin; Asteraceae; Double-Blind Method; Female; Humans; Lentigo; Melanins; Melanosis; Middle Aged; Plant Extracts; Plant Leaves; Skin Cream; Skin Lightening Preparations | 2015 |
1 other study(ies) available for arbutin and Lentigo
| Article | Year |
|---|---|
DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency.
Modulation of melanogenesis in the melanocytes can be achieved using chemicals that share structural homologies with the substrate tyrosine and as thus competitively inhibit the catalytic function of tyrosinase. We have developed a new tyrosinase inhibitor, deoxyArbutin (dA), based on this premise. DeoxyArbutin demonstrates effective inhibition of mushroom tyrosinase in vitro with a Ki that is 10-fold lower that hydroquinone (HQ) and 350-fold lower than arbutin. In a hairless, pigmented guinea pig model, dA demonstrated rapid and sustained skin lightening that was completely reversible within 8 weeks after halt in topical application. In contrast, HQ induced a short but unsustained skin lightening effect whereas kojic acid and arbutin exhibit no skin lightening effect. Results from a panel of safety tests supported the overall establishment of dA as an actionable molecule. In a human clinical trial, topical treatment of dA for 12 weeks resulted in a significant or slight reduction in overall skin lightness and improvement of solar lentigines in a population of light skin or dark skin individuals, respectively. These data demonstrate that dA has potential tyrosinase inhibitory activity that can result in skin lightening and may be used to ameliorate hyperpigmentary lesions. Topics: Agaricales; Animals; Arbutin; Cell Proliferation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Escherichia coli; Guinea Pigs; Humans; Hydroquinones; Hyperpigmentation; Immunosuppressive Agents; Kinetics; Lentigo; Light; Lymph Nodes; Mice; Mice, Inbred CBA; Models, Chemical; Monophenol Monooxygenase; Skin; Skin Pigmentation; Time Factors | 2005 |